Chromadex Corp Stock Price, News & Analysis

ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, has announced its participation in the 17th Annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel, California on October 29th, 2024. CEO Rob Fried and CFO Ozan Pamir will deliver a presentation at 2:00pm PT (5:00pm ET). The event will showcase 150 companies and include private one-on-one meetings with institutional investors. ChromaDex management will be available for individual meetings throughout the day. Interested parties can watch the live presentation through a provided webcast link and access additional company information through the LD Micro profile page.

ChromaDex Corp. (NASDAQ:CDXC) announced that Dr. Yasmeen Nkrumah-Elie, their Global Director of External Research, has been honored with the inaugural Trailblazing Woman Award by Radicle Science and the Council for Responsible Nutrition (CRN). This award recognizes Dr. Nkrumah-Elie's contributions to the dietary supplement and functional food industry through leadership, innovation, and mentorship.

Dr. Nkrumah-Elie has led ChromaDex's External Research Program (CERP) to become an industry-leading initiative with nearly 300 research collaborations worldwide, over 30 published clinical trials, and several intellectual property opportunities. She is also active in various industry organizations, advocating for diversity, equity, and inclusion.

The award highlights Dr. Nkrumah-Elie's commitment to advancing scientific excellence, promoting diversity, and mentoring the next generation of female leaders in the industry.

ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ and healthy-aging research, has announced its participation in the Lytham Partners Fall 2024 Investor Conference. CEO Rob Fried will engage in a fireside chat on October 1, 2024, at 1:15 PM ET, moderated by Sean McGowan from Roth Capital Partners. The webcast will be accessible via a provided link and the company's website.

Additionally, Fried and Wesley Yu, VP of Finance, will host virtual one-on-one meetings with investors. Interested parties can arrange meetings through Lytham Partners or register for the event online. This participation underscores ChromaDex's commitment to investor relations and showcases its position in the healthy-aging research sector.

ChromaDex Corp. (NASDAQ:CDXC) has appointed Ozan Pamir as Chief Financial Officer, effective October 21, 2024. Mr. Pamir will oversee all corporate finance matters, including accounting, strategic financial planning, and investor relations, reporting directly to CEO Rob Fried. Prior to joining ChromaDex, Pamir served as CFO of 180 Life Sciences, where he played a key role in the company's NASDAQ listing and managed funding rounds. He has also worked with two early-stage biotech companies as CFO and board member, and was previously VP of Investment Banking at a leading independent investment bank. Mr. Pamir holds an Economics and Finance degree from McGill University and is a CFA Charterholder.

ChromaDex Corp. (NASDAQ:CDXC) has announced the expansion of its pharmaceutical-grade Niagen® (nicotinamide riboside chloride) IV and injection offerings to 14 additional leading wellness clinics across the United States. This follows the successful debut of quantities in select clinics last month. Wells Pharma of Houston, a U.S. FDA-registered 503B outsourcing facility, will compound and distribute the product, branded as Niagen+, exclusively to these clinics with a prescription.

Niagen, ChromaDex's flagship ingredient, is clinically proven to elevate NAD+ levels, important for cellular health. The IV and injection formulations offer rapid and efficient delivery, outperforming NAD+ IV in a pilot clinical study with superior tolerability, 75% shorter infusion time, and a significant 20% increase in whole blood NAD+ levels. Several clinic directors have expressed excitement about the potential of Niagen IV in health optimization and longevity treatments.

ChromaDex Corp. (NASDAQ:CDXC) celebrates its 25th anniversary as a pioneer in NAD+ research and healthy aging solutions. Founded in 1999, ChromaDex has evolved from an analytical testing company to a leader in developing proprietary ingredients for dietary supplements. The company's flagship product, Tru Niagen®, is the top NAD+ supplement for healthy aging in the U.S., with over 8 million bottles sold.

Key achievements include:

• Licensing patents for Dr. Charles Brenner's nicotinamide riboside (NR) research in 2012
• Launching Niagen®, the first patented form of NR, in 2013
• Introducing pharmaceutical-grade Niagen+™ for intravenous therapy in 2024
• Establishing the ChromaDex External Research Program (CERP™), which has facilitated over 275 research agreements globally
• Building a portfolio of 90+ patents related to NAD+ precursors

To mark this milestone, ChromaDex is offering a 25% discount on lifelong Tru Niagen® subscriptions and one-time purchases until September 12, 2024.

ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, will participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, August 29, 2024, at 2:00 PM EDT. The event will feature a presentation by key executives, including CEO Rob Fried, Interim CFO James Lee, and VP Finance Wesley Yu.

The live presentation will cover ChromaDex's latest investor information, followed by a Q&A session. While live event registration may be , a replay will be available on the company's investor website. Interested parties can register for the event using the provided link, and are advised to use the latest version of Google Chrome for optimal connectivity.

This virtual roadshow offers an opportunity for stakeholders, investors, and followers to gain insights into ChromaDex's current initiatives and future prospects in the field of healthy aging and NAD+ research.

ChromaDex Corp. (NASDAQ:CDXC) has secured U.S. Patent number 10,000,520 C1 for the composition of matter of salt forms of NMNH (dihydronicotinamide mononucleotide), a precursor to NAD+. This patent, co-owned with Queen's University Belfast, grants ChromaDex exclusive rights to the disodium salt form of NMNH. The company now has over 80 patents related to NAD+ precursors, including its flagship ingredient Niagen® (nicotinamide riboside).

NMNH is distinct from NMN, which was banned as a dietary supplement by the FDA in 2022. While NMNH has shown promise in preclinical studies, further research is needed to determine its oral bioavailability and safety as a dietary supplement. Currently, NMNH's legal status as a dietary supplement is questionable due to lack of proper FDA notification as a new dietary ingredient (NDI).

ChromaDex Corp. (NASDAQ:CDXC) reported strong Q2 2024 financial results, with total net sales of $22.7 million, up 12% year-over-year. Tru Niagen® sales reached $18.6 million, a 10% increase. The company achieved a gross margin of 60.2% and reduced operating expenses by $0.7 million compared to the prior year quarter. ChromaDex reported an approximately breakeven net loss and positive Adjusted EBITDA of $1.6 million.

Key developments include receiving U.S. FDA Orphan Drug Designation for nicotinamide riboside chloride to treat Ataxia Telangiectasia, and launching Niagen+, a pharmaceutical-grade product line. The company also introduced Niagen+ NAD+ Test Kits for healthcare practitioners. For the full year 2024, ChromaDex expects 10-15% revenue growth and slightly improved gross margins.